Samsung Medical Center: Prostatic Hyperplasia trials

The registry lists 12 Prostatic Hyperplasia studies with Samsung Medical Center as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 1Phase 4 5No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the ProstateCompletedNCT03460873
• Retrospective Review a Comprehensive Case Database of HoLEP Procedure Performed by a Single SurgeonCompletedNCT01604148
• Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic Benign Prostatic Hyperplasia (BPH)Status unknownNCT01404637Not applicable
• Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)CompletedNCT01301599Phase 4
• Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS/BPH Refractory to Tamsulosin 0.2mgStatus unknownNCT00954889Not applicable
• Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)CompletedNCT00922506Phase 4
• Impact of 80 W KTP Laser Vaporization Prostatectomy on Severity of Obstruction in Benign Prostatic HyperplasiaCompletedNCT00908427Not applicable
• Efficacy Study of HoLEP and TURP on LUTS Secondary to BPHCompletedNCT00877669Phase 2
• Evaluation of Symptom-specific Goal AchievementCompletedNCT00836823Phase 4
• Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic ObstructionCompletedNCT00827814Phase 4
• Effects of Chronic Use of Doxazosin in Men With Benign Prostatic HyperplasiaCompletedNCT00730418Not applicable
• The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic HyperplasiaWithdrawnNCT00687388Phase 4